{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-related+Maculopathy&page=4",
    "query": {
      "condition": "Age-related Maculopathy",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 669,
    "total_pages": 67,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-related+Maculopathy&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-related+Maculopathy&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T08:00:03.045Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02510794",
      "title": "Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2015-09-28",
      "completion_date": "2019-03-28",
      "has_results": true,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 50,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02510794"
    },
    {
      "nct_id": "NCT02951351",
      "title": "Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age-related Macular Degeneration",
        "Diabetic Macular Edema",
        "Injection Site",
        "Injection Site Infection",
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Proparacaine",
          "type": "DRUG"
        },
        {
          "name": "Conjunctival culture",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2016-10-12",
      "completion_date": "2018-02",
      "has_results": true,
      "last_update_posted_date": "2023-04-12",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02951351"
    },
    {
      "nct_id": "NCT00564902",
      "title": "The Zeaxanthin and Visual Function Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age Related Macular Degeneration",
        "Cognition Disorders"
      ],
      "interventions": [
        {
          "name": "3R 3'R Zeaxanthin",
          "type": "DRUG"
        },
        {
          "name": "Lutein",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Lutein and Zeaxanthin",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Chrysantis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "45 Years to 90 Years"
      },
      "enrollment_count": 60,
      "start_date": "2007-11",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2012-03-29",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 1,
      "location_summary": "North Chicago, Illinois",
      "locations": [
        {
          "city": "North Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00564902"
    },
    {
      "nct_id": "NCT00349739",
      "title": "Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Anecortave Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-01",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2010-01-15",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00349739"
    },
    {
      "nct_id": "NCT00764738",
      "title": "Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OCT, Multifocal ERG, Microperimetry",
          "type": "DEVICE"
        },
        {
          "name": "Ranibizumab Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Retina Macula Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2008-10",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2020-09-22",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00764738"
    },
    {
      "nct_id": "NCT01524874",
      "title": "Comparative Effectiveness of Vitamin D and Repletion Strategies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypovitaminosis D",
        "Insulin Resistance",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Vitamin D3",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Bastyr University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 66,
      "start_date": "2010-08",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2012-02-02",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 2,
      "location_summary": "Kailua-Kona, Hawaii • Kenmore, Washington",
      "locations": [
        {
          "city": "Kailua-Kona",
          "state": "Hawaii"
        },
        {
          "city": "Kenmore",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01524874"
    },
    {
      "nct_id": "NCT01310686",
      "title": "Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Wet AMD"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "West Coast Retina Medical Group, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2011-04",
      "completion_date": "2019-06",
      "has_results": false,
      "last_update_posted_date": "2018-10-12",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01310686"
    },
    {
      "nct_id": "NCT00403156",
      "title": "Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Imatinib Mesylate /Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vitreous -Retina- Macula Consultants of New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "51 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2006-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-31",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403156"
    },
    {
      "nct_id": "NCT03465709",
      "title": "Pegcetacoplan (APL-2) in Neovascular AMD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2018-02-14",
      "completion_date": "2019-04-05",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 4,
      "location_summary": "Beverly Hills, California • Hagerstown, Maryland • Cleveland, Ohio + 1 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03465709"
    },
    {
      "nct_id": "NCT00733304",
      "title": "An Extension to Study MD7108240",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2008-06-25",
      "completion_date": "2009-09-09",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-10-12T08:00:03.045Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Sacramento, California • Winter Haven, Florida + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00733304"
    }
  ]
}